rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    RVMD
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Revolution Medicines Wins EU Nod for Rasonque in Pancreatic Cancer
      Nov 17Yahoo FinanceRVMD
      Revolution Medicines CFO Jack Anders sells $6.7 million in stock
      Nov 14Investing.comRVMD
      Revolution Medicines officer sells $162,200 in shares
      Nov 13Investing.comRVMD
      Here's How Much $1000 Invested In Revolution Medicines 5 Years Ago Would Be Worth Today
      Nov 12BenzingaRVMD
      Revolution Medicines: RASONQUE Is Off To A Strong Start, But Expectations Are High (RVMD)
      Nov 12Seeking AlphaRVMD
      Revolution Medicines at guggenheim healthcare innovation conference: launch gains
      Nov 10Investing.comRVMD
      Wall Street Analysts Think Revolution Medicines (RVMD) Could Surge 33.34%: Read This Before Placing a Bet
      Nov 10Yahoo FinanceRVMD
      Revolution Medicines stock reiterated at Buy by Stifel, $230 target
      Nov 9Investing.comRVMDSF
      Why Royalty Pharma Investors Could Be the Quiet Winners From Revolution Medicines' Groundbreaking Pancreatic Cancer Drug | The Motley Fool

      Revolution Medicines has a big drug making headlines, and Royalty Pharma gets a bite of the action without doing anything at all.

      Nov 8The Motley FoolRVMD
      Revolution Medicines (RVMD) Rallies On RASONQUE Launch As Fair Value Debate Heats Up

      Revolution Medicines (RVMD) is back in focus after third quarter earnings showed revenue of US$197.56 million and a net loss of US$407.46 million, driven largely by the recent RASONQUE launch. Investors have reacted quickly to the RASONQUE launch and earnings update, with Revolution Medicines’ share price up 8.24% over the past day even as the 30 day share price return is down 4.28% and the 90 day share price return is down 6.27%. At the same time, the year to date share price return of...

      Nov 7Yahoo FinanceRVMD
      Revolution Medicines Stock Gets A Lift From Pancreatic Cancer Drug Launch

      Revolution Medicines reported third quarter 2026 revenue of US$197.56 million, driven entirely by the early U.S. launch of RASONQUE for metastatic pancreatic cancer. The business continued to post substantial net losses and a higher loss per share over both the quarter and the first nine months of the year. The same product launch that generated US$197.6 million of net product revenue in roughly five weeks also treated more than 5,000 U.S. patients and secured preferred status in NCCN...

      Nov 7Yahoo FinanceRVMD
      Why is Revolution Medicines stock surging today?
      Nov 6Investing.comRVMD
      Revolution Medicines Q3 Earnings: Stellar Company And Drug, But The Market Knows It (RVMD)

      Revolution Medicines posts $198M Q3 revenue from RASONQUE’s launch, but the rich valuation limits upside. Click to read this most recent analysis of RVMD stock.

      Nov 5Seeking AlphaRVMD
      Revolution Medicines (RVMD) Q3 2026 Earnings Call Transcript

      Motley Fool Press Release.

      Nov 5The Globe and MailRVMD
      This pancreatic cancer treatment is on track for ‘one of the best drug launches of all time’
      Nov 5MarketWatchRVMD
      Revolution Medicines, Inc. Q3 2026 Earnings Call Summary
      Nov 5Yahoo FinanceRVMD
      What Revolution Medicines (RVMD) Said on Its Q3 Earnings Call
      Nov 5Yahoo FinanceRVMD
      Futures: Dow Leads Postelection Rally; Three Giants Are Buys

      Stocks from many sectors flash buy signals, but avoid this area.

      Nov 4Investor's Business DailyAAPLAMZNCRWVMSFTRVMDSPCX
      Revolution Medicines Q3 2026 Earnings Call Transcript
      Nov 4BenzingaRVMD
      Revolution Medicines, Inc. (RVMD) Reports Q3 Loss, Beats Revenue Estimates
      Nov 4Yahoo FinanceRVMD
      12 Health Care Stocks Moving In Wednesday's After-Market Session
      Nov 4BenzingaRVMD
      Revolution Medicines Reports Third Quarter 2026 Financial Results and Update on Corporate Progress
      Nov 4Yahoo FinanceRVMD
      Revolution Medicines in focus: Rasonque launch on earnings test
      Nov 4Investing.comRVMD
      Tango: Upgrading 'Buy' Based On ESMO 2026 Vopimetostat PDAC Data And Pathway Advancement Clarity
      Oct 30Seeking AlphaRVMDTNGX
      Could Revolution Medicines Be a Millionaire-Maker Stock?
      Oct 29Yahoo FinanceRVMD
      Revolution Medicines officer sells $431,946 in shares
      Oct 28Investing.comRVMD
      Revolution Medicines to Participate in November 2026 Investor Conferences
      Oct 27Yahoo FinanceRVMD
      Revolution Medicines director sells $1.96 million of stock
      Oct 27Investing.comRVMD
      Revolution Medicines (RVMD) Stock Looks Above Fair Value Today
      Oct 24Yahoo FinanceRVMD
      Revolution Medicines (RVMD) Following New Pancreatic Cancer Data Looks Undervalued
      Oct 24Yahoo FinanceRVMD
      Tango Therapeutics Sinks 13% on Pancreatic Cancer Data It Says “Surpass Any Published PDAC Datasets”
      Oct 23Yahoo FinanceRVMDTNGX
      Here’s How Much You Would Have Made Owning Revolution Medicines Stock In The Last 5 Years
      Oct 23BenzingaRVMD
      Revolution Medicines presents subgroup data from pancreatic cancer trial
      Oct 23Investing.comRVMD
      Revolution Medicines Presents Overall Survival Data for RASONQUE™ (daraxonrasib) Across Subgroups in Previously Treated Metastatic Pancreatic Cancer at ESMO 2026

      Expanding on the unprecedented final results previously reported from the Phase 3 RASolute 302 trial, the exploratory subgroup analyses showed RASONQUE consistently provided an overall survival benefit compared with chemotherapy across key subgroups, including patients with no identified tumor RAS mutation​Findings presented as late-breaking abstract during Proffered Paper session REDWOOD CITY, Calif., Oct. 23, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commerc

      Oct 23Yahoo FinanceRVMD
      How Tango Improved On Revolution's 'Unprecedented' Results

      Tango Therapeutics beat expectations Friday for its combination using Revolution Medicines' newly approved drug in pancreatic cancer.

      Oct 23Investor's Business DailyRVMDTNGX
      Revolution Medicines to Report Financial Results for Third Quarter 2026 After Market Close on November 4, 2026
      Oct 21Yahoo FinanceRVMD
      Revolution Medicines Begins Phase 3 Trial For Advanced Lung Cancer Treatment
      Oct 20BenzingaRVMD
      Revolution Medicines (RVMD) Has an Approved Cancer Drug. Can Its $38 Billion Valuation Deliver?
      Oct 20Yahoo FinanceRVMD
      Revolution Medicines begins phase 3 trial for lung cancer drug
      Oct 20Investing.comRVMD
      Revolution Medicines Begins Treating Patients in Phase 3 RASolve 308 Trial Evaluating Zoldonrasib in Combination with Pembrolizumab and Chemotherapy as First-Line Treatment for Patients with Metastatic RAS G12D Non-Squamous Non-Small Cell Lung
      Oct 20Yahoo FinanceRVMD
      Revolution Medicines Stock In Focus After EU Drug Backing
      Oct 17Yahoo FinanceRVMD
      Why Moderna Stock, Novavax, and Revolution Medicines Are Slumping Today

      Moderna and Revolution Medicines have upcoming catalysts that could help sustain their gains, even as biotech stocks retreat.

      Oct 16Barron'sMRNANVAXRVMD
      What's Going On With Revolution Medicines Stock Friday? - Revolution Medicines (NASDAQ:RVMD)

      William Blair sets $226 price target for Revolution Medicines (RVMD) following Rasonque approval and major oncology expansion plans.

      Oct 16BenzingaRVMD
      William Blair initiates Revolution stock with outperform on RAS franchise
      Oct 16Investing.comRVMD
      These 2 Stocks Have Run Circles Around the Magnificent Seven This Year, and Wall Street Says There Is More Upside Ahead | The Motley Fool

      Innovation pays off.

      Oct 15The Motley FoolRVMD
      Erasca, Inc: The Discount RevMed? (NASDAQ:ERAS)
      Oct 15Seeking AlphaERASRVMD
      Revolution Medicines' Europe efforts signal solo launch ambitions for cancer drug
      Oct 15ReutersONCRVMD
      Revolution Medicines receives EU committee backing for pancreatic cancer drug
      Oct 15Investing.comRVMD
      RevMed’s Breakthrough Pancreatic Cancer Drug Gets European Nod
      Oct 15BloombergRVMD
      EMA recommends approval of Revolution's pancreatic cancer drug
      Oct 15ReutersRVMD

      This is the newest page. Registered accounts read further back.